Overview

Effect of BMS-986165 on the Blood Levels of Metformin

Status:
Completed
Trial end date:
2021-03-30
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to investigate the effects of BMS-986165 on the drug levels of metformin in healthy participants.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
BMS-986165
Metformin
Criteria
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Healthy, as determined by having no clinically significant deviation from normal in
medical history, physical examination, electrocardiograms, vital signs, and clinical
laboratory determinations

- Body mass index of 18.0 kg/m^2 to 32.0 kg/m^2, inclusive, and body weight ≥ 50 kg, at
screening

- Must agree to follow specific methods of contraception, if applicable

Exclusion Criteria:

- Any significant acute or chronic medical condition that presents a potential risk to the
participant and/or may compromise the objectives of the study, including a history of or
active liver disease

Other protocol-defined inclusion/exclusion criteria apply